Axi-cel CAR-T therapy extends EFS in patients with R/R large B-cell lymphoma
21 July 2021
- The randomised phase 3 trial included 359 patients that were randomly assigned a single fusion of axi-cel or standard-of-care therapies for R/R large B-cell lymphoma
- Results showed a significant EFS improvement (HR = 0.39; P<0.0001) among patients assigned axi-cel
- Axi-cel also exhibited a safety profile consistent with that observed with use of the agent in the third-line setting
Click here to learn more.
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: JUL2021CW001